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Screening
Edward Nuñes: The authors’ recommendation that
programs screen patients for potential mental health
problems on intake is sensible. I’m convinced, as they
are, that line clinicians in substance abuse programs
can develop the clinical sophistication necessary to
recognize mood disorders and make appropriate 
referrals. 
Patricia Penn: I agree. We also need to keep in mind
that symptoms often emerge during the treatment
process. Clinicians should monitor the client for symp-
toms at all times, not just during the initial screening.
Nuñes: The SCL-90 symptom checklist is a good
instrument for making the initial assessment, although
it only assesses symptom levels—it doesn’t point to
diagnoses.
Penn: There is a real need for more clinician-friendly
screening tools. In one of our programs, the coun-
selors have combined the most effective and efficient
parts of several instruments into our own hybrid
screener. We also have tried CAAPE, the Comprehensive
Addictions and Psychological Evaluation developed
by Dr. Norman Hoffman, which is designed 
specifically to diagnose co-occurring disorders, 
and it looks promising. Dr. Hoffman’s screens, which
also include one for adolescents, are available at
www.evinceassessment.com.
William Haning, III: In my hospital, we screen patients
with the SCID [Structured Clinical Interview for
DSM-IV-TR] at the very outset, then follow up with
some of the faster, cheaper screeners. In the commu-
nity facility where I work, we use a variety of cheap,
fast screens. Interestingly, the results in terms of patient
profile turn out to be similar in both places. The more
comprehensive SCID does not lead to a greater num-
ber of diagnoses. I wonder sometimes if its results war-
rant the extra effort it requires. The computerized ver-
sion of the SCID is quicker, and we’re satisfied that
personnel at a bachelor’s level or even below can man-
age it nicely.
Nuñes: I would also advocate for the CAAPE or the
Hopkins Symptom Checklist.
The makers of SCID, Drs. Bob Spitzer, Janet
Williams, and Michael Frist, have also developed a
couple of simplified versions for use in primary care.
One is called PRIME-MD, which is clinician-
administered and brief. The other is called PHQ,
Patient’s Health Questionnaire, which the patient fills
out. A colleague here at Columbia, Dr. Carlos Blanco,
is adding modules on attention deficit disorder and
gambling, concerns which aren’t present in the pri-
mary care versions but are important to substance
abuse providers.
Diagnosis
Haning: Unfortunately, a fair number of people
are still convinced that all mood disorders in sub-
stance abusers derive from the substance use and/or
some character pathology that will resolve after a few
years of progressive work. It isn’t so. There is a con-
siderable comorbidity that really does need to get
treated.
Penn: Some patients feel relieved when they receive
a mood disorder diagnosis, because it helps explain
why they have felt bad for so long. Others, of course,
find the diagnosis difficult to accept and resist it.
Haning: Some understand that having a mood dis-
order is going to complicate their prognosis and give
them a harder time in life. They will contest the diag-
nosis with you.
Nuñes: Patients also resist because plenty of stigma
still surrounds mood disorders. A line I hear occa-
sionally is, “I’m not crazy, I’m a drug addict. I don’t
need to see any shrink.”
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Haning: The biggest risk in discussing a potential
mood disorder diagnosis with a patient is that for
some, it provides a rationale for not acknowledging
drug dependence. That’s not a reason to withhold the
information, but it does mean we need to educate the
patient about the implications of having two inter-
active illnesses simultaneously.
Theoretical models and treatment
Haning: I was taken with the authors’ discussion of
the kindling model, because it could explain a pat-
tern we observe clinically. When methamphetamine
users begin treatment, they typically are psychotic or
hypomanic and subsequently become depressed. They
feel low for a long time, but after somewhere between
10 and 14 months, they perk up, their affect comes
alive, and they begin to have less difficulty paying
attention and concentrating. The kindling theory,
along with imaging studies by Drs. Linda Chang 
and Nora Volkow [Chang et al., 2002; Volkow et al.,
2001], suggest to me that the temporal pattern 
of recovery might reflect the gradual resolution of
methamphetamine-induced brain inflammation. 
Penn: Our patients abuse an average of three and a
half drugs each, including amphetamines. We see the
same pattern: a long struggle, and then recovery
becomes self-reinforcing after a year to 14 months.
Haning: Patients don’t need to be completely absti-
nent the whole year to achieve this watershed, but
almost.
Penn: The authors’ discussion of the theories relating
to mood and substance abuse disorders is absorbing,
and solving that puzzle will lead to better interven-
tions. In clinical settings, however, we should beware
of getting caught up in chicken-and-egg debates about
which is primary. They can be a distraction from treat-
ment. I like to ask clients, “What do you think is caus-
ing this?” or “How does your substance use affect your
mood, and vice versa?” The client’s impression gives
you an idea how to proceed in treatment.
Nuñes: I also ask patients what their experience with
the drug has been, and look very hard for evidence
that the substance abuse makes the mood syndrome
worse. Often it does, not when the patient is taking
the drug, but afterwards.
I work in a motivational framework, so I try to
steer patients toward connecting their drug abuse and
mental health problems for themselves. Some find it
difficult. I’m thinking, in particular, about a patient
who has bipolar illness and alcoholism. Medication
controls his affective disorder reasonably well when
he’s not drinking, but when he starts to drink, he dete-
riorates. We have to constantly remind him that he
has been down this path before—we know what the
outcome will be. If we can get him to see that con-
nection, it’ll make a big difference.
Haning: The trick for therapists is to get somebody
who has lived from moment to moment to look a year
into the future, have confidence that things will get
better, and just hang in there until they do. In my
experience, a major rationale for giving medica-
tions such as antidepressants and anticonvulsants is
to keep patients coming back for their appointments—
whether the meds really suppress symptoms or have
only a placebo effect.
Penn: At La Frontera, we have noticed that many
people come into our intensive program for a month
or two or three, go away for a while, come back, go
away, and so on. They seem to need that time to
test out and practice what they learn in therapy and
let it sink in. We try to maintain an open-door pol-
icy so clients can come back as needed.
Haning: We compel patients to rewrite their relapse
prevention program each time they come back. We
also get into long arguments with insurers about what
they see as a revolving door and we see as a progres-
sive acclimatization to recovery.
Penn: I was glad the authors mentioned a group CBT
model for treating co-occurring disorders. We also
need a model that can accommodate rolling enroll-
ment. With nonrolling enrollment models, we must
ask people to wait for weeks just to get into group
support. This doesn’t work—people don’t come back.
Mix or match?
Haning: Some treatment programs mix all their
patients together; others provide separate groups for
patients with mood disorders. I think separation is
best. These patients need a safe environment to dis-
cuss their medications and the elements of their treat-
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ment that are specific to their co-occurring disorders.
In mixed groups, they can get the worst of both worlds:
not taking full responsibility for their bad decision-
making around drug abuse, and not getting their
symptoms taken seriously when there is a need to
modify the medication regimen or enhance 
cognitive-behavioral strategies. Also, referring too
often to ‘my bipolar disorder’ or ‘my manic depres-
sion’ is an invitation to be ostracized.
Penn: This issue also comes up in relation to outside
support groups. For example, even though a 12-step
pamphlet encourages people to take their medica-
tions as prescribed, a lot of individual groups don’t
subscribe to that. These groups often don’t know how
to deal with people who have a mental illness. Our
patients, especially those with serious mental illness,
have lots of problems and generally have trouble find-
ing sponsors. They have had happier experiences with
Smart Recovery [www.smartrecovery.org], which uses
cognitive-behavioral treatment methods that apply
to both mood and substance abuse disorders. They
like the program because it uses a trained facilitator
to keep the meetings contained and ensure that every-
one is respected.
Haning: I agree. The key to success in these programs
is having somebody who is quasi-professional, either
on the periphery of the meeting or actually facili-
tating it to ensure the fundamental needs of the attend-
ing population are met.
Penn: We also need more good modules for train-
ing counselors in co-occurring disorders. Online
sources would be especially helpful. They could reach
people everywhere, including rural areas, where there
is a big problem finding people who are competent
in treating co-occurring disorders. &
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